I'm very interested to see whether or not Admelog can chip away at sales as quickly as Basaglar has chipped away at Sanofi's Lantus. Harjes: Right now, it doesn't seem like that'll be the case. Sanofi's biosimilar is there, it launched earlier this year, but Humalog sales actually grew 13% year over year within the quarter. For now, at least, it's hanging on just fine.